Home › Funds › Burkehill Global Management, LP › MBX
Burkehill Global Management, LP position in MBX
MBX BIOSCIENCES INC · Health Care
Burkehill Global Management, LP reported holding 100,000 shares of MBX (MBX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$5.9M, representing 0.26% of its reported portfolio and ranking #49 among its reported holdings. Burkehill Global Management, LP has disclosed MBX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Burkehill Global Management, LP's MBX position evolved
Burkehill Global Management, LP first disclosed a stake in MBX in Q3 2025 at 100,000 shares (US$1.8M). The position peaked in Q3 2026 at 100,000 shares, worth US$5.9M. Across 5 filings, Burkehill Global Management, LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 100,000 shares valued at US$5.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 100.00K | $1.75M | New |
| Q4 2025 | 100.00K | $3.15M | Hold |
| Q1 2026 | 100.00K | $2.98M | Hold |
| Q2 2026 | 100.00K | $5.52M | Hold |
| Q3 2026 | 100.00K | $5.86M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MBX and 13F data
MBX (MBX BIOSCIENCES INC) is a Health Care company. 57 other funds we track also report a position in MBX — the largest reported positions include Frazier Life Sciences Management, L.P. (US$389.9M), Paradigm Biocapital Advisors LP (US$221.2M), NEA Management Company, LLC (US$211.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MBX
- Frazier Life Sciences Management, L.P. 6.65M sh · $389.94M · Q3 2026
- Paradigm Biocapital Advisors LP 3.77M sh · $221.17M · Q3 2026
- NEA Management Company, LLC 3.61M sh · $211.88M · Q3 2026
- ORBIMED ADVISORS LLC 3.07M sh · $180.25M · Q3 2026
- NVP Associates, LLC 2.14M sh · $125.23M · Q3 2026
- Aaron Wealth Advisors LLC 1.18M sh · $68.92M · Q3 2026
- Kynam Capital Management, LP 934.80K sh · $54.80M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 873.49K sh · $51.20M · Q3 2026
- Parkman Healthcare Partners LLC 716.54K sh · $42.00M · Q3 2026
- TCG Crossover Management, LLC 650.00K sh · $38.10M · Q3 2026
- Deep Track Capital, LP 640.00K sh · $37.52M · Q3 2026
- BRAIDWELL LP 398.95K sh · $23.39M · Q3 2026
More on Burkehill Global Management, LP
FAQ
How long has Burkehill Global Management, LP held MBX?
Burkehill Global Management, LP has disclosed MBX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Burkehill Global Management, LP's current position in MBX?
As of Q3 2026, Burkehill Global Management, LP holds 100.00K shares of MBX (MBX BIOSCIENCES INC), valued at $5.86M, representing 0.26% of its reported portfolio and ranking #49.
Has Burkehill Global Management, LP been buying or selling MBX?
In the latest 13F filing (Q3 2026), Burkehill Global Management, LP held unchanged its position in MBX. The position peaked in Q3 2026 at 100.00K shares.
Which other funds hold MBX?
Other major institutional holders of MBX include Frazier Life Sciences Management, L.P., Paradigm Biocapital Advisors LP, NEA Management Company, LLC, among 57 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.